Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Mol Cancer Ther. 2014 Dec 17;14(2):513–522. doi: 10.1158/1535-7163.MCT-14-0208

Figure 4. Increased sensitivity to sunitinib following biochemical and pharmacological inhibition of EZH2 in ccRCC cell lines.

Figure 4

A) Western blot analysis showing the efficiency of EZH2 knockdown in 786-0 cell line. B) Specific knockdown of EZH2 in 786-0 cells are more sensitive to sunitinib as compare to the scrambled template control, 786-0_shRNA. C) 786-0 and 786-0R cell lines were treated with either sunitinib, GSK126 or both for 48hr. Bar chart indicates significant decrease in cell viability in combination treatment arm as compared to the single agents alone. D) Combination index values for sunitinib and GSK126 in 786-0 (CI=0.224) and 786-0R (CI=0.224). E) Western blot analysis shows a decrease in E2F-1 with single treatments or combination in 786-0 cells however, in the resistant cell lines, expression levels are significantly low in combination treatment. F) Western blot analysis showing increase in EZH2 expression in sunitinib resistant cell lines, 786-0R compared to the parental 786-0.